



# IL-6



**Figure 1. Control of IL-6 in patients stratified by variable baseline elevations.** Inflammatory marker and cytokine expression was assessed by multiplex ELISA at days 0, 3 and 14 (or discharge). Expression values from individuals are connected with solid lines, with deceased individuals indicated in red. Values are plotted with exclusion of patients with baseline IL-6 expression lower than 10 (n=11) and 40 (n=6) pg/mL. Statistics: Paired ratio t-tests were used to compare the expression levels at days 3 and 14 to baseline. \*:  $P < 0.05$ , \*\*\*:  $P < 0.001$ , n.s.: not significant.



**Figure 2. Control of inflammatory markers and cytokines following infliximab therapy in a patient without prior steroid or remdesivir exposure.**

**Table 1. Change in cytokine levels at Days 3 and 14**

Day 3			Day 14		
Cytokine	P-value	FDR Critical value	Cytokine	P-value	FDR Critical value
TNFa	0.000071	0.001	IP-10	0.00055	0.001
IL-27	0.00012	0.002	CRP	0.003039	0.002
IP-10	0.00016	0.003	IL-27	0.0088	0.003
CRP	0.00058	0.004	CXCL9	0.0088	0.004
IFNy	0.002	0.005	Ferritin	0.013907	0.005
Ferritin	0.002098	0.006	IL-22	0.017	0.006
CXCL9	0.0088	0.007	IL-5	0.021	0.007
IL-12p40	0.011	0.008	GROa	0.026	0.008
IL-10	0.013	0.009	TNFa	0.056	0.009
Eotaxin	0.035	0.01	VEGF-A	0.064	0.01
IL-4	0.067	0.011	IL-10	0.072	0.011
IL-6	0.069	0.012	IL-3	0.073	0.012
GM-CSF	0.081	0.013	G-CSF	0.15	0.013
MCP-1	0.089	0.014	IL-7	0.2	0.014
MDC	0.097	0.015	Fractalkine	0.22	0.015
MCP-3	0.097	0.016	FLT-3L	0.22	0.016
M-CSF	0.098	0.017	IL-17E/IL-25	0.22	0.017
IL-8	0.14	0.018	IL-6	0.24	0.018
IL-17A	0.16	0.019	IL-15	0.26	0.019
Fractalkine	0.16	0.02	IL-17F	0.26	0.02
EGF	0.17	0.021	GM-CSF	0.27	0.021
IL-13	0.17	0.022	IL-4	0.28	0.022
VEGF-A	0.18	0.023	FGF-2	0.29	0.023
GROa	0.21	0.024	Eotaxin	0.33	0.024
FLT-3L	0.22	0.025	EGF	0.33	0.025
sCD4OL	0.26	0.026	IL-18	0.33	0.026
G-CSF	0.3	0.027	IL-1RA	0.33	0.027
IL-9	0.38	0.028	TNFB	0.38	0.028
IL-12p70	0.39	0.029	MCP-3	0.39	0.029
IL-18	0.41	0.03	IL-12p40	0.4	0.03
TGFa	0.41	0.031	IL-9	0.41	0.031
IL-1a	0.42	0.032	IFN-a2	0.46	0.032
FGF-2	0.45	0.033	RANTES	0.48	0.033
TNFB	0.45	0.034	IL-1B	0.5	0.034
IL-22	0.46	0.035	sCD4OL	0.53	0.035
IFN-a2	0.49	0.036	IL-8	0.55	0.036
IL-2	0.52	0.037	IL-2	0.65	0.037
IL-1B	0.66	0.038	TGFa	0.66	0.038
IL-17E/IL-25	0.66	0.039	MIP-1a	0.67	0.039
IL-15	0.68	0.04	PDGF-AB/BB	0.68	0.04
IL-5	0.7	0.041	IL-13	0.69	0.041
MIP-1B	0.7	0.042	MIP-1B	0.73	0.042
PDGF-AB/BB	0.71	0.043	MDC	0.74	0.043
IL-17F	0.88	0.044	IL-17A	0.77	0.044
PDGF-AA	0.89	0.045	M-CSF	0.78	0.045
IL-7	0.9	0.046	MCP-1	0.82	0.046
IL-3	0.92	0.047	IL-12p70	0.83	0.047
RANTES	0.93	0.048	IL-1a	0.84	0.048
IL-1RA	0.94	0.049	IFNy	0.87	0.049
MIP-1a	0.98	0.05	PDGF-AA	0.98	0.05

A 5% false-discovery rate (FDR) adjustment was applied using the Benjamini-Hochberg method. The cytokines are ordered in ascending p-value; green highlighting denotes statistical significance after the FDR correction.

**Table 2: Pearson correlation between dynamic changes in IP-10 with other cytokines**

Total (n=17)		Lymphopenic (n=13)		Recovered* by day 3 (n=6)		Non-lymphopenic (n=4)	
MIG/CXCL9	0.65	MIG/CXCL9	0.84	MIG/CXCL9	0.98	IL-12p40	0.99
IL-15	0.60	IL-3	0.71	M-CSF	0.83	sCD40L	0.95
FLT-3L	0.60	IL-15	0.70	IL-1RA	0.74	EGF	0.93
IL-12p40	0.58	M-CSF	0.67	G-CSF	0.70	FGF-2	0.91
IL-3	0.57	FLT-3L	0.62	IL-3	0.63	MDC	0.90
M-CSF	0.56	RANTES	0.62	IL-15	0.63	IFN- $\alpha$ 2	0.90
MDC	0.53	IL-17F	0.61	IL-10	0.59	IL-5	0.85
IFN- $\alpha$ 2	0.51	IL-18	0.61	IL-8	0.59	IL-17E/IL-25	0.84
IL-5	0.50	GRO $\alpha$	0.61	TNF $\alpha$	0.57	FLT-3L	0.77
IL-18	0.48	IL-12p40	0.59	IFN $\gamma$	0.56	PDGF-AB/BB	0.73
IL-1RA	0.45	IL-10	0.55	FLT-3L	0.43	IL-1RA	0.71
RANTES	0.45	PDGF-AA	0.54	IL-6	0.42	TGF $\alpha$	0.70
IL-10	0.45	IL-8	0.53	IL-17F	0.38	IL-4	0.66
sCD40L	0.44	IFN $\gamma$	0.50	CRP	0.36	PDGF-AA	0.60
TNF $\alpha$	0.42	IL-17A	0.46	GRO $\alpha$	0.31	Ferritin	0.60
TGF $\alpha$	0.41	sCD40L	0.46	IL-18	0.30	MCP-1	0.54
PDGF-AA	0.40	MDC	0.46	IL-12p40	0.28	Fractalkine	0.53
IL-8	0.36	MIP-1 $\alpha$	0.44	sCD40L	0.24	TNF $\alpha$	0.50
MIP-1 $\alpha$	0.35	IL-1RA	0.43	MIP-1 $\beta$	0.20	VEGF-A	0.50
PDGF-AB/BB	0.35	PDGF-AB/BB	0.42	RANTES	0.15	RANTES	0.49
IL-17E/IL-25	0.35	IFN- $\alpha$ 2	0.40	MCP-3	0.07	IL-8	0.49
IFN $\gamma$	0.34	IL-12p70	0.38	PDGF-AA	0.07	IL-27	0.43
GRO $\alpha$	0.30	FGF-2	0.35	Fractalkine	-0.04	M-CSF	0.39
IL-12p70	0.29	TNF $\alpha$	0.35	IL-22	-0.07	IL-9	0.39
FGF-2	0.29	MCP-1	0.34	Eotaxin	-0.10	IL-1 $\beta$	0.28
MCP-1	0.27	IL-6	0.34	IL-17A	-0.12	IL-10	0.28
IL-2	0.26	TGF $\alpha$	0.33	IL-13	-0.15	GM-CSF	0.27
IL-27	0.24	IL-4	0.33	IL-12p70	-0.17	MCP-3	0.19
IL-4	0.23	Eotaxin	0.33	TNF $\beta$	-0.18	IL-3	0.16
Eotaxin	0.23	IL-5	0.32	IL-2	-0.21	MIP-1 $\beta$	0.16
IL-7	0.21	IL-2	0.31	IL-4	-0.21	Eotaxin	0.16
GM-CSF	0.21	G-CSF	0.31	IL-1 $\alpha$	-0.26	IL-15	0.13
EGF	0.21	IL-1 $\alpha$	0.28	IFN- $\alpha$ 2	-0.33	IL-1 $\alpha$	0.05
G-CSF	0.19	GM-CSF	0.28	IL-7	-0.34	IL-7	0.01
IL-6	0.19	IL-7	0.25	PDGF-AB/BB	-0.39	MIP-1 $\alpha$	0.00
CRP	0.17	IL-1 $\beta$	0.24	MDC	-0.40	IL-13	-0.02
VEGF-A	0.17	EGF	0.22	Ferritin	-0.43	IFN $\gamma$	-0.08
IL-17A	0.15	VEGF-A	0.21	MCP-1	-0.43	IL-12p70	-0.09
IL-9	0.14	IL-9	0.18	EGF	-0.44	IL-18	-0.10
IL-1 $\beta$	0.12	CRP	0.17	VEGF-A	-0.45	TNF $\beta$	-0.12
MIP-1 $\beta$	0.11	MIP-1 $\beta$	0.17	IL-5	-0.46	IL-2	-0.12
IL-17F	0.09	IL-27	0.14	TGF $\alpha$	-0.53	IL-6	-0.17
IL-22	0.06	IL-22	0.14	IL-27	-0.53	<b>MIG/CXCL9</b>	<b>-0.22</b>
MCP-3	0.04	IL-13	0.12	GM-CSF	-0.59	G-CSF	-0.25
IL-13	0.02	IL-17E/IL-25	0.11	MIP-1 $\alpha$	-0.61	IL-22	-0.31
TNF $\beta$	-0.01	TNF $\beta$	0.07	IL-17E/IL-25	-0.63	GRO $\alpha$	-0.39
IL-1 $\alpha$	-0.01	MCP-3	-0.15	IL-9	-0.74	IL-17F	-0.45
Ferritin	-0.04	Fractalkine	-0.23	IL-1 $\beta$	-0.81	CRP	-0.53
Fractalkine	-0.21	Ferritin	-0.29	FGF-2	-0.85	IL-17A	-0.53

Pearson r correlation coefficients were calculated between changes in levels of IP-10 with changes in levels of other cytokines between day 3 and baseline. Correlations in each subset of patients are displayed in descending order.

\*Recovered to an absolute lymphocyte count of at least 1.0

**Table 3: Secondary Infections following infliximab-abda therapy**

Patients	Diagnosis	Diagnostic certainty	Organism(s) if isolated	Time to diagnosis (days)	Time to treatment (days)	Duration of antimicrobial therapy (days)	Death due to secondary infection(s)
1	VAP	Suspected	NA	5	5	6	No
2	VAP	Confirmed	<i>Pseudomonas aeruginosa</i>	3	4	5	NA
3	CAPA	Probable	<i>Aspergillus fumigatus</i>	3	3	41	NA
	CMV viremia	Confirmed	CMV	25	NA	NA	
	VAP	Confirmed	<i>Acinetobacter baumannii</i>	26	32	9	
4	VAP	Confirmed	MRSA, MDR-Klebsiella	2	3	14	Confirmed
	HSV pneumonitis	Confirmed	HSV	At autopsy	NA	NA	
5	VAP	Suspected	NA	12	13	15	NA
	Tracheostomy site SSTI	Confirmed	Polymicrobial	21	25	6	
	CMV viremia	Confirmed	CMV	24	NA	NA	
6	VAP	Confirmed	Polymicrobial	1	1	9	Suspected
	CAPA	Probable	NA	6	6	3	
7	VAP	Suspected	NA	5	5	22	NA
	Invasive candidiasis	Suspected	NA	15	23	7	
8	CAP	Confirmed	<i>Streptococcus pneumoniae</i>	1	1	6	Suspected
	HSV pneumonitis	Confirmed	HSV-1	14	16	13	
	CAPA	Possible	<i>Aspergillus niger</i>	35	22	13	

VAP: Ventilator-associated pneumonia; CAPA: COVID-19-associated pulmonary aspergillosis; CMV: Cytomegalovirus; MRSA: Methicillin-resistant *Staphylococcus aureus*; HSV: Herpes simplex virus; CAP: Community-acquired pneumonia; MDR: Multidrug resistant; SSTI: Skin and soft tissue infection; NA: Not applicable.